Novavax ( (NVAX) ) has provided an update.
Novavax, Inc. has acknowledged a recent analyst report discussing the expected U.S. COVID-19 vaccine market for the upcoming 2024-2025 season. The company clarified that although it predicts a market similar to the previous year, it has not changed or reconfirmed its financial guidance for the full year of 2024.
For an in-depth examination of NVAX stock, go to TipRanks’ Stock Analysis page.